Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALX Oncology
Biotech
ALX lays off 30% of staff to pay for more trials of CD47 blocker
ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 blocker.
James Waldron
Mar 5, 2025 9:40am
Flagship-backed biotechs name new leaders—Chutes & Ladders
Nov 15, 2024 8:30am
ALX's fizzling CD47 response rate sends stock spiraling down
Aug 1, 2024 5:34am
ALX links CD47 drug to improved response rate in solid tumors
Oct 3, 2023 6:15am
Illumina nets new CEO—Chutes & Ladders
Sep 8, 2023 9:30am
ALX follows Gilead in axing cancer trials as data disappoint
Aug 11, 2023 9:05am
